1644. A potent broadly neutralizing antibody isolated from human memory B-cells binding to conserved site IV on the RSV F protein.
Session: Oral Abstract Session: Respiratory and Gastroenteritis Viruses
Friday, October 5, 2018: 2:00 PM
Room: W 2002
Background: Respiratory syncytial virus (RSV) infection is a major public health burden for infants and the elderly worldwide. Currently, there are no approved vaccines and only one moderately effective marketed antibody (Synagis®) for the prevention of RSV infection in high risk infants. Sampling the human antibody repertoire has led to the realization that the RSV fusion (F) protein in its pre-fusion conformation is the preferred target for potent neutralizing antibodies and thus makes the protein an attractive candidate for vaccine developers.

Methods:

We report the isolation of a potent and broad RSV neutralizing monoclonal antibody (mAb), which was discovered through molecular cloning of cultured RSV post-fusion F protein-baited single-sorted human memory B cells. The epitope for the mAb was mapped to RSV F protein using various methods; including X-ray crystallography, alanine scan, and RSV escape mutant generation

Results:

The mAb binds to both RSV pre- and post-fusion F proteins at site IV and can neutralize RSV A and B laboratory strains with sub-nanomolar potency, superior to that of Palivizumab. Antigenic site IV is conserved between pre- and post-fusion F proteins in both RSV A and B subgroups, and sequence alignment showed that the mAb binding site was conserved in >1,000 RSV A and B clinical isolates. In vivo cotton rat studies demonstrated protection of both the upper and lower respiratory tract of antibody-infused animals challenged with either RSV A or RSV B.

Conclusion:

Overall, the fully human mAb we have isolated has great potential to be developed for passive immune-prophylaxis in infants. A prevalent view of the RSV scientific community is that RSV neutralizing mAbs in human sera primarily target the pre-fusion F protein and predominantly bind antigenic site Ø. In contrast, our finding demonstrates that very broad and potent RSV neutralizing mAb can also recognize sites common to pre- and post-fusion F proteins. Furthermore, the RSV F antigenic site IV presents a neutralizing epitope which is highly conserved. Therefore, it is worthwhile to consider site IV, in addition to site Ø, in the design of RSV subunit vaccines.

Kalpit Vora, PhD1, Zhifeng Chen, PhD2, Hua-Poo Su, PhD2, Aimin Tang, MS2, Kara Cox, MS2, Cheryl Callahan, MS2, Lan Zhang, PhD2, Sangita Patel, MS2, Debbie Nahas, MS2, Mike Citron, PhD3, Pedro Cejas, PhD2, Ryan Swoyer, MS2, Bin Luo, MS2, Michael Eddins, MS2, John Reid, MS2, Arthur Fridman, PhD2, Jennifer Galli, MS2, Scott Cosmi, MS4, Govindarajan Dhanasekeran, PhD2, Zhiyun Wen, MS2, Xi He, MS2, Dai Wang, PhD2, Gwen Heidecker, MS2, Jessica Flynn, PhD2, James Cook, PhD2, Stephen Soisson, PhD2, Danilo Casimiro, PhD2, Andrew Bett, PhD2, Wade Blair, PhD2, Daniel Distefano, MS2 and Christopher Haines, PhD2, (1)Merck & Co., Inc., Kenilworth, NJ, (2)Merck Research Laboratories, Kenilworth, NJ, (3)Vaccines Research, Merck Research Lab, West Point, PA, (4)Eurofins Lancaster Laboratories Professional Scientific Services, Lancaster, PA

Disclosures:

K. Vora, Merck: Employee , Salary .

Z. Chen, Merck: Employee , Salary .

H. P. Su, Merck: Employee , Salary .

A. Tang, Merck: Employee , Salary .

K. Cox, merck: Employee , Salary .

C. Callahan, Merck: Employee , Salary .

L. Zhang, Merck: Employee , Salary .

S. Patel, Merck: Employee , Salary .

D. Nahas, merck: Employee , Salary .

M. Citron, merck: Employee , Salary .

P. Cejas, merck: Employee , Salary .

R. Swoyer, Merck: Employee , Salary .

B. Luo, merck: Employee , Salary .

M. Eddins, Merck: Employee , Salary .

J. Reid, Merck: Employee , Salary .

A. Fridman, Merck: Employee , Salary .

J. Galli, Merck: Employee , Salary .

S. Cosmi, Merck: Independent Contractor , Salary .

G. Dhanasekeran, Merck: Employee , Salary .

Z. Wen, Merck: Employee , Salary .

X. He, Merck: Employee , Salary .

D. Wang, Merck: Employee , Salary .

G. Heidecker, Merck: Employee , Salary .

J. Flynn, Merck: Employee , Salary .

J. Cook, merck: Employee , Salary .

S. Soisson, Merck: Employee , Salary .

D. Casimiro, Merck: Employee , Salary .

A. Bett, Merck: Employee , Salary .

W. Blair, Merck: Employee , Salary .

D. Distefano, Merck: Employee , Salary .

C. Haines, Merck: Employee , Salary .

Previous Abstract | Next Abstract >>

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.